Venture Fund Viii, L.P.Arch... Net Worth

The estimated Net Worth of Venture Fund Viii, L.P.Arch... is at least $505 Thousand dollars as of 13 September 2022. Venture Arch owns over 5,000,000 units of Codiak BioSciences stock worth over $504,684 and over the last 4 years Venture sold CDAK stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Venture Arch CDAK stock SEC Form 4 insiders trading

Venture has made over 3 trades of the Codiak BioSciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 5,000,000 units of CDAK stock worth $7,500,000 on 13 September 2022.

The largest trade Venture's ever made was buying 5,000,000 units of Codiak BioSciences stock on 13 September 2022 worth over $7,500,000. On average, Venture trades about 1,821,667 units every 242 days since 2020. As of 13 September 2022 Venture still owns at least 8,854,098 units of Codiak BioSciences stock.

You can see the complete history of Venture Arch stock trades at the bottom of the page.

Insiders trading at Codiak BioSciences

Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch..., and Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.

What does Codiak BioSciences do?

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Venture Arch stock trades at Metacrine and Codiak BioSciences

Codiak BioSciences executives and stock owners

Codiak BioSciences executives and other stock owners filed with the SEC include:

• Dr. Douglas Edward Williams Ph.D.,
  Pres, CEO & Director
• Dr. Sriram Sathyanarayanan Ph.D.,
  Chief Scientific Officer
• Yalonda Howze,
  Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
• Dr. Benny Sorensen M.D., Ph.D.,
  Member of Scientific Advisory Board & Consultant
• Dr. David J. Mauro M.D., Ph.D.,
  Chief Medical Officer
• Dr. Benny Sorensen,
  Member of Scientific Advisory Board & Consultant
• Richard Brudnick,
  Chief Bus. Officer & Head of Corp. Strategy
• Nicole Barna,
  Sr. VP of HR
• Christopher J. M. Taylor,
  VP of Investor Relations & Corp. Communications
• Dr. Konstantin Konstantinov,
  Chief Technology Officer
• Linda Cathavina Bain CPA,
  CFO & Treasurer
• Arundathy N. Pandite,
  Director
• Anne Virginie Eggimann,
  Director
• Ventures Fund V General Par...,
  
• Richard Brudnick,
  See Remarks
• Venture Fund Viii, L.P.Arch...,
  
• Charles L Cooney,
  Director
• Kyriazi Theo Melas,
  Director
• Briggs Morrison,
  Director
• Eric S Lander,
  Director
• Jason Haddock,
  Director
• Karen Bernstein,
  Director
• Steven Gillis,
  Director
• Permanent Fund Corp Alaska,
  
• Benny Sorensen,
  See Remarks
• Nicole Barna,
  See Remarks
• Jennifer J. Wheler,
  Chief Medical Officer
• Ajay Verma,
  See Remarks
• David J Mauro,
  Chief Medical Officer
• Douglas E Williams,
  President & CEO
• Konstantin Konstantinov,
  Chief Technology Officer
• Linda Bain,
  Chief Financial Officer
• Sriram Sathyanarayanan,
  Chief Scientific Officer
• Yalonda Howze,
  See Remarks